Prasugrel versus clopidogrel antiplatelet therapy after acute coronary syndrome: Matching treatments with patients

American Journal of Cardiovascular Drugs

Volumn 12, Issue 2, 2012, Pages 83-91

  Tcheng, James E ^a   Mackay, Steven M ^b  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b NAVAL MEDICAL CENTER PORTSMOUTH   (United States)

Author keywords

acute coronary syndrome; antiplatelet therapy; myocardial infarction.; prasugrel; stroke; thienopyridines, clopidogrel

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; CYTOCHROME P450; CYTOCHROME P450 2C19; FIBRINOGEN RECEPTOR ANTAGONIST; PRASUGREL;

ACUTE CORONARY SYNDROME; BLEEDING; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; HUMAN; LOADING DRUG DOSE; MAINTENANCE THERAPY; NON ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; REVIEW;

ACUTE CORONARY SYNDROME; CLINICAL TRIALS, PHASE II AS TOPIC; CLINICAL TRIALS, PHASE III AS TOPIC; HEMORRHAGE; HUMANS; PIPERAZINES; PLATELET AGGREGATION INHIBITORS; RECURRENCE; THIOPHENES; TICLOPIDINE;

EID: 84858694893     PISSN: 11753277     EISSN: 1179187X     Source Type: Journal    
DOI: 10.2165/11594600-000000000-00000     Document Type: Review

References (32)

1. Bhatt DL, Topol EJ. Scientific and therapeutic adVances in antiplatelet therapy. Nat Rev Drug Discov 2003 Jan; 2 (1): 15-28 (Pubitemid 37361621)
2. Bhatt DL. Intensifying platelet inhibition: navigating between Scylla and Charybdis. N Engl J Med 2007 Nov 15; 357 (20): 2078-81 (Pubitemid 350106717)
3. Barker CM, Price MJ. Antiplatelet therapy in acute coronary syndromes. Curr Cardiol Rep 2008 Jul; 10 (4): 327-33
4. Kushner FG, Hand M, Smith Jr SC, et al. 2009 Focused updates: ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction (updating the 2004 guideline and 2007 focused update) and ACC/ AHA/SCAI guidelines on percutaneous coronary intervention (updating the 2005 guideline and 2007 focused update): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2009 Dec 1; 120 (22): 2271-306
5. Wright RS, Anderson JL, Adams CD, et al. 2011 ACCF/AHA Focused update of the guidelines for the management of patients with unstable angina/non- ST-elevation myocardial infarction (updating the 2007 guideline): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2011 May 10; 123 (18):2022-60
6. Steinhubl SR, Tan WA, Foody JM, et al. Incidence and clinical course of thrombotic thrombocytopenic purpura due to ticlopidine following coronary stenting. EPISTENT Investigators. Evaluation of Platelet IIb/IIIa Inhibitor for Stenting. JAMA 1999 Mar 3; 281 (9): 806-10 (Pubitemid 29113740)
7. Bertrand ME, Rupprecht HJ, Urban P, et al. Double-blind study of the safety of clopidogrel with and without a loading dose in combination with aspirin compared with ticlopidine in combination with aspirin after coronary stenting: the clopidogrel aspirin stent international cooperative study (CLASSICS). Circulation 2000 Aug 8; 102 (6): 624-9 (Pubitemid 30640661)
8. Angiolillo DJ, Guzman LA, Bass TA. Current antiplatelet therapies: benefits and limitations. Am Heart J 2008 Aug; 156 (2 Suppl.): S3-9
9. Serebruany VL, Steinhubl SR, Berger PB, et al. Variability in platelet responsiveness to clopidogrel among 544 individuals. J Am Coll Cardiol 2005 Jan 18; 45 (2): 246-51 (Pubitemid 40094733)
10. Mega JL, Close SL, Wiviott SD, et al. Cytochrome P450 genetic polymorphisms and the response to prasugrel: relationship to pharmacokinetic, pharmacodynamic, and clinical outcomes. Circulation 2009 May 19; 119 (19): 2553-60
11. Giorgi MA, Cohen Arazi H, Gonzalez CD, et al. Beyond efficacy: pharmacokinetic differences between clopidogrel, prasugrel and ticagrelor. Expert Opin Pharmacother 2011 Jun; 12 (8): 1285-95
12. Wiviott SD, Antman EM, Braunwald E. Prasugrel. Circulation 2010 Jul 27; 122 (4): 394-403
13. Roden DM, Stein CM. Clopidogrel and the concept of high-risk pharmacokinetics. Circulation 2009 Apr 28; 119 (16): 2127-30
14. Sugidachi A, Ogawa T, Kurihara A, et al. The greater in vivo antiplatelet effects of prasugrel as compared to clopidogrel reflect more efficient generation of its active metabolite with similar antiplatelet activity to that of clopidogrel's active metabolite. J Thromb Haemost 2007 Jul; 5 (7): 1545-51 (Pubitemid 46965386)
15. Wallentin L, Varenhorst C, James S, et al. Prasugrel achieves greater and faster P2Y12receptor-mediated platelet inhibition than clopidogrel due to more efficient generation of its active metabolite in aspirin-treated patients with coronary artery disease. Eur Heart J 2008 Jan; 29 (1): 21-30
16. Payne CD, Li YG, Small DS, et al. Increased active metabolite formation explains the greater platelet inhibition with prasugrel compared to high-dose clopidogrel. J Cardiovasc Pharmacol 2007 Nov; 50 (5): 555-62 (Pubitemid 350146459)
17. Farid NA, Smith RL, Gillespie TA, et al. The disposition of prasugrel, a novel thienopyridine, in humans. Drug Metab Dispos 2007 Jul; 35 (7): 1096-104 (Pubitemid 46956429)
18. Niitsu Y, Jakubowski JA, Sugidachi A, et al. Pharmacology of CS-747 (prasugrel, LY640315), a novel, potent antiplatelet agent with in vivo P2Y12 receptor antagonist activity. Semin Thromb Hemost 2005 Apr; 31 (2): 184-94 (Pubitemid 40605193)
19. Wiviott SD, Antman EM, Winters KJ, et al. Randomized comparison of prasugrel (CS-747, LY640315), a novel thienopyridine P2Y12 antagonist, with clopidogrel in percutaneous coronary intervention: results of the Joint Utilization of Medications to Block Platelets Optimally (JUMBO)-TIMI 26 trial. Circulation 2005 Jun 28; 111 (25): 3366-73 (Pubitemid 40931949)
20. Wiviott SD, Trenk D, Frelinger AL, et al. Prasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: the Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation-Thrombolysis in Myocardial Infarction 44 trial. Circulation 2007 Dec 18; 116 (25): 2923-32 (Pubitemid 350291199)
21. Wiviott SD, Antman EM, Gibson CM, et al. Evaluation of prasugrel compared with clopidogrel in patients with acute coronary syndromes: design and rationale for the TRial to assess Improvement in Therapeutic Outcomes by optimizing platelet InhibitioN with prasugrel Thrombolysis In Myocardial Infarction 38 (TRITON-TIMI 38). Am Heart J 2006 Oct; 152 (4): 627-35 (Pubitemid 44396884)
22. Wiviott SD, Braunwald E, McCabe CH, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes.NEngl J Med 2007 Nov 15; 357 (20): 2001-15 (Pubitemid 350106708)
23. EFFIENT (prasugrel) tablets. US prescribing information. Parsippany (NJ)and Indianapolis (IN): Daiichi Sankyo, Inc. and Eli Lilly and Company, 2010
24. Montalescot G, Wiviott SD, Braunwald E, et al. Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial. Lancet 2009 Feb 28; 373 (9665): 723-31
25. Wiviott SD, Braunwald E, Angiolillo DJ, et al. Greater clinical benefit of more intensive oral antiplatelet therapy with prasugrel in patients with diabetes mellitus in the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-Thrombolysis in Myocardial Infarction 38. Circulation 2008 Oct 14; 118 (16): 1626-36
26. Wiviott SD, Braunwald E, McCabe CH, et al. Intensive oral antiplatelet therapy for reduction of ischaemic events including stent thrombosis in patients with acute coronary syndromes treated with percutaneous coronary intervention and stenting in the TRITON-TIMI 38 trial: a subanalysis of a randomised trial. Lancet 2008 Apr 19; 371 (9621): 1353-63
27. Ajani AE, Lefkovits J. Approaching an age of reason with antiplatelet therapy. Lancet 2008 Apr 19; 371 (9621): 1315-6 (Pubitemid 351522847)
28. Stone GW, McLaurin BT, Cox DA, et al. Bivalirudin for patients with acute coronary syndromes. N Engl J Med 2006 Nov 23; 355 (21): 2203-16 (Pubitemid 44791162)
29. Subherwal S, Bach RG, Chen AY, et al. Baseline risk of major bleeding in non- ST-segment-elevation myocardial infarction: the CRUSADE (Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early implementation of the ACC/AHA Guidelines) bleeding score. Circulation 2009 Apr 14; 119 (14): 1873-82
30. Mehta SR, Bassand JP, Chrolavicius S, et al.Dose comparisons of clopidogrel and aspirin in acute coronary syndromes. N Engl JMed 2010 Sep 2; 363 (10): 930-42
31. Food and Drug Administration. FDA Drug Safety Communication: reduced effectiveness of Plavix (clopidogrel) in patients who are poor metabolizers of the drug. 2010 [online]. Available fromURL: PostmarketDrugSafetyInformation forPatientsandProviders/ucm203888.htm [Accessed 2011 Jun 15]
32. Holmes Jr DR, Dehmer GJ, Kaul S, et al. ACCF/AHA Clopidogrel clinical alert: approaches to the FDA ''boxed warning'': a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the American Heart Association. Circulation 2010 Aug 3; 122 (5): 537-57